Bacterial and Tuberculous Infections of Nervous System DRG Reimbursement

DRG 095 addresses bacterial and tuberculous infections of the nervous system with a Complication or Comorbidity, encompassing conditions like bacterial meningitis and tuberculous meningitis with additional complicating diagnoses. It matters for inpatient reimbursement because the presence of a Complication or Comorbidity increases relative resource use and thereby affects Medicare hospital payment under the Diagnosis-Related Group system.

DRG 095 Overview

DRG 095 covers hospital admissions for bacterial and tuberculous infections of the nervous system when a Complication or Comorbidity is present. This includes conditions such as bacterial meningitis, intracranial abscesses, and tuberculous meningitis with coexisting complications that increase resource use. The Diagnosis-Related Group classification influences reimbursement by grouping clinically similar cases with comparable expected costs for Medicare payment. Accurate coding of the infection type and coexisting Complication or Comorbidity affects payment assignment under inpatient prospective payment.

Acute antimicrobial regimen optimization trials: randomized or adaptive studies comparing durations, routes (IV vs IV-to-oral switch), and combinations of antibiotics in adults hospitalized with bacterial or tuberculous central nervous system (CNS) infections (e.g., bacterial meningitis, tuberculoma, tuberculous meningitis). These trials enroll patients during the index hospitalization with confirmed or highly suspected CNS infection to determine the shortest effective therapy and best step-down strategies while monitoring relapse, neurologic complications, and adverse events. Findings directly inform inpatient length of stay, antibiotic utilization, and readmission risk — key drivers of cost and resource use for providers and payers managing DRG 095 patients.
Adjunctive therapies and supportive care intervention studies: controlled trials evaluating non-antimicrobial interventions given during acute care, such as corticosteroid timing/dosing strategies, intracranial pressure management protocols, or rapid diagnostic-guided treatment algorithms for severe bacterial or tuberculous CNS infections. These studies typically recruit critically ill inpatients with altered mental status or raised intracranial pressure to assess impact on neurologic outcomes, mortality, need for ICU-level care, and complication rates (hydrocephalus, infarcts). Results are relevant to clinicians and payers because improvements in acute neurologic outcomes and reductions in ICU days or neurosurgical interventions can lower costs and improve DRG-level resource allocation.
Post-discharge functional outcomes and health services research: prospective cohort studies and comparative effectiveness research following survivors of CNS bacterial or tuberculous infections after hospital discharge to measure long-term neurologic disability, cognitive impairment, rehospitalization, and outpatient service utilization. These studies focus on diverse populations including older adults, patients with HIV or immunosuppression, and those with prolonged inpatient stays, assessing rehabilitation needs, adherence to prolonged therapy (especially for tuberculous CNS disease), and predictors of readmission. Payers and health systems use these data to plan post-acute care, allocate rehabilitation resources, design follow-up protocols to reduce costly readmissions, and evaluate bundled payment or care pathway effectiveness for DRG 095.

Acute antimicrobial regimen optimization trials: randomized or adaptive studies comparing durations, routes (IV vs IV-to-oral switch), and combinations of antibiotics in adults hospitalized with bacterial or tuberculous central nervous system (CNS) infections (e.g., bacterial meningitis, tuberculoma, tuberculous meningitis). These trials enroll patients during the index hospitalization with confirmed or highly suspected CNS infection to determine the shortest effective therapy and best step-down strategies while monitoring relapse, neurologic complications, and adverse events. Findings directly inform inpatient length of stay, antibiotic utilization, and readmission risk — key drivers of cost and resource use for providers and payers managing DRG 095 patients.
Adjunctive therapies and supportive care intervention studies: controlled trials evaluating non-antimicrobial interventions given during acute care, such as corticosteroid timing/dosing strategies, intracranial pressure management protocols, or rapid diagnostic-guided treatment algorithms for severe bacterial or tuberculous CNS infections. These studies typically recruit critically ill inpatients with altered mental status or raised intracranial pressure to assess impact on neurologic outcomes, mortality, need for ICU-level care, and complication rates (hydrocephalus, infarcts). Results are relevant to clinicians and payers because improvements in acute neurologic outcomes and reductions in ICU days or neurosurgical interventions can lower costs and improve DRG-level resource allocation.
Post-discharge functional outcomes and health services research: prospective cohort studies and comparative effectiveness research following survivors of CNS bacterial or tuberculous infections after hospital discharge to measure long-term neurologic disability, cognitive impairment, rehospitalization, and outpatient service utilization. These studies focus on diverse populations including older adults, patients with HIV or immunosuppression, and those with prolonged inpatient stays, assessing rehabilitation needs, adherence to prolonged therapy (especially for tuberculous CNS disease), and predictors of readmission. Payers and health systems use these data to plan post-acute care, allocate rehabilitation resources, design follow-up protocols to reduce costly readmissions, and evaluate bundled payment or care pathway effectiveness for DRG 095.

OpenPayer

Summary & Overview

Bacterial and Tuberculous Infections of Nervous System with CC: Inpatient Reimbursement Overview

DRG 095 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes